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ABSTRACT 
Aims: Monocyte chemoattractant protein-1 (MCP-1) is a major chemotactic factor for 
hepatic stellate cells (HSCs) associated with hepatic fibrosis. In this study, among 
several fibrogenetic factors derived from BECs, MCP-1 produced by the biliary innate 
immune system, was found to be most critical in the histogenesis of hepatic fibrogenesis. 
Methods: Using cultured human biliary epithelial cells (BECs), the expression of 5 
fibrogenetic factors including MCP-1 on stimulation with Toll-like receptor (TLR) 
ligands, inflammatory cytokines, or bile acids was examined. Moreover, in situ 
detection of MCP-1 and α-smooth muscle actin (αSMA) proteins was performed using 
sections from normal and diseased livers by immunohistochemistry. Results: All 
fibrogenetic factors were detected in BECs, but only MCP-1 expression was 
upregulated, by all the TLR ligands, IL-1β, and TNF-α. Proliferating bile ductules in 
interface areas expressed MCP-1 in diseased livers accompanying αSMA-positive 
activated HSCs. Conclusions: Bile ductules proliferate in various hepatobiliary diseases 
and its significance is still unknown. This study demonstrated that BECs in bile ductules 
could produce MCP-1, particularly, via biliary innate immunity, suggesting that MCP-1 
derived from BECs plays an important role in the recruitment of HSCs to interface areas 
and the activation of HSCs resulting in the progression of periportal fibrosis. 
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Introduction 
Hepatic fibrosis is a major feature of advanced liver diseases and defines the 
prognosis. Hepatic fibrosis spreads within portal tracts and also periportal areas in 
patients with hepatitic and cholestatic liver diseases. Although periportal fibrosis is 
thought to be associated with the accumulation and activation of hepatic stellate cells 
(HSCs), its mechanisms are not fully understood. HSCs undergo differentiation toward 
an activated phenotype and this process is enhanced by soluble mediators such as 
platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β), 
which mediate the increase in cell proliferation and extracellular matrix production.1, 2 
Then, HSCs migrate into damaged areas in response to a chemokine, secreting 
monocyte chemotactic protein-1 (MCP-1/CCL2) that recruits monocytes and 
lymphocytes.3 Moreover, MCP-1 triggers the migration of activated, but not quiescent, 
HSCs in a dose-dependent manner. Experiments in vitro using HSCs isolated from 
normal human livers revealed that MCP-1-dependent signals were not transduced by the 
chemokine receptor of MCP-1, CCR2, and may be mediated by alternative chemokine 
receptors.3 Recently, Ramm et al.,4 reported that hepatocyte-derived MCP-1 induced by 
a hydrophobic bile acid, taurocholate, could result in the recruitment of HSCs in 
cholestatic liver injury as the major fibrogenesis in a pediatric cholestatic liver disease 
such as biliary atresia. In contrast, biliary epithelial cells (BECs) may promote 
fibrogenesis by a number of mechanisms including the synthesis of matrix constituents 
and the release of mediators such as MCP-1, PDGF-BB, TGF-β, connective tissue 
growth factor (CTGF), and endothelin-1.5 The role of BECs in the pathogenesis of 
hepatic fibrosis, particularly periportal fibrosis accompanying interface hepatitis in 
various hepatobiliary diseases including chronic viral hepatitis (CVH) and primary 
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biliary cirrhosis (PBC), is speculated to be important to the disease’s progression, but its 
precise mechanism is still unknown.  
 Our previous study demonstrated that human BECs possess several 
inflammatory cytokine receptors and Toll-like receptors (TLRs) and produced cytokines 
and chemokines in response to inflammatory cytokines and pathogen-associated 
molecular patterns (PAMPs), respectively.6-9 In particular, bile ductules located between 
interlobular bile ducts in portal tracts and bile canaliculi in hepatocytes are frequently 
increased in number under a variety of pathologic conditions of the liver and take part in 
various immunological responses and the pathogenesis of biliary diseases.10-12 This 
ductular reaction is speculated to be closely associated with hepatic fibrosis, particularly 
periportal fibrosis accompanying interface hepatitis, but its precise mechanism is still 
unknown. In this study, we examined the possibility that BECs produce MCP-1 and 
play a role in fibrogenesis in periportal areas via MCP-1 production. 
 
Materials and Methods 
Cultured human BECs: Two human intrahepatic BEC lines were established 
from explanted livers with PBC as described previously.7 These cell lines had been 
confirmed to be BECs by the expression of biliary-type cytokeratins. 
Stimulation: Cultured BECs were stimulated with inflammatory cytokines, 
PAMPs, and bile acids (Table 1). As a NF-κB inhibitor, isohelenin (30μM, Calbiochem) 
was added to the culture medium before the stimulation We previously confirmed that 
BECs possess the receptors for all these cytokines and PAMPs.6 Cell samples for the 
examination of mRNA as shown below were prepared at 2hrs after the stimulation. 
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 RT-PCR and real-time PCR: For the evaluation of mRNAs of MCP-1, 
PDGF-B, CTGF, TGF-β1, endothelin-1, and GAPDH (internal control) in cultured 
BECs, total RNA was isolated from BECs and RT-PCR and real-time quantitative PCR 
were performed according to a standard protocol using specific primers (Table 1).  
 Enzyme-linked immunosorbent assay (ELISA): Cultured BECs were 
stimulated with LPS, Pam3CSK4, poly(I:C), and IL-1β for 24 hours and supernatants 
were tested for human MCP-1 by ELISA (Biosource International, Camarillo, CA, 
USA).  
Liver tissues: A total of 26 surgical or wedge liver biopsy specimens were 
obtained from patients with CVH (n=8, HCV-related, male/female=5/3, average age 
58y.o., F1/F2=4/4), PBC (n=5, all female, average age 68y.o., Nakanuma’s 
classification13 Stage 2/3=4/1, Scheuer’s classification Stage 1/2=2/3), and congenital 
hepatic fibrosis (CHF, n=5, used as a case of activated HSC-poor case14, male/female 
4/1, average age 23y.o.), and 6 cases with no significant histopathological change 
("normal liver").  
Immunohistochemistry: Deparaffinized sections were pretreated in Target 
Retrieval Solution (Dako, Tokyo, Japan) and incubated with a primary antibody against 
MCP-1 (10μg/ml; Abcam, Tokyo, Japan) or α-smooth muscle actin (αSMA, activated 
HSC marker) (1μg/ml, Dako) and then Envision-HRP (Dako) was used. No positive 
staining was obtained when the primary antibody was replaced with an isotype-matched, 
non-immunized immunoglobulin.  
The simultaneous detection of combined CCR2 and αSMA, and CCR2 and 
CD68, was evaluated by double fluorescence immunohistochemical staining. After 
incubation with the antibodies for these combinations, rabbit antibody (CCR2, 1:400, 
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Epitomics, Burlingame, CA, USA) and mouse antibodies (αSMA and CD68, Dako) 




Detection of MCP-1 in cultured human BECs: RT-PCR revealed that all 
fibrogenic cytokines were detected in human BECs in the basal cultures (Fig.1). 
Quantitative PCR revealed that only MCP-1 was upregulated following stimulation with 
all PAMPs and two cytokines (IL-1β and TNF-α)(Fig2). Moreover, ELISA 
demonstrated that the concentration of MCP-1 protein in the supernatants was increased 
by these stimulants (Fig.3). None of the bile acids upregulated the expression of MCP-1 
(Fig.2). The Pam3CSK4-induced upregulation of MCP-1 mRNA was significantly 
inhibited by pretreatment with the NF-κB inhibitor(Fig.2). 
In situ detection of MCP-1 and activated HSCs: MCP-1 was mainly expressed 
in bile ducts and that the majority of proliferating bile ductules predominantly expressed 
MCP-1 in periportal and interface areas in cases of CVH and PBC (Fig.4). Moreover, 
αSMA-positive cells (activated HSCs) were scattered around these bile ductules (Fig.4). 
These characteristic findings were made in CVH and PBC accompanying interface 
hepatitis and ductular reaction, but rare or absent in normal livers. Periportal 
hepatocytes were also frequently positive for MCP-1, but the intensity was similar or 
less than that in bile ductules. In contrast, MCP-1-positive bile ductules were not found 
in CHF. Moreover, the expression of αSMA was limited in portal tracts and 
αSMA-positive HSCs were not found in CHF. 
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Characterization of CCR2-expressing cells: Fluorescence double 
immunostaining revealed that cells double positive for CD68 and CCR2 were scattered 
mostly in interface areas of CVH and PBC, but cells double positive for αSMA and 
CCR2 were not found in any area (Fig.5). 
   
Discussion 
Chronic liver injury is generally characterized by inflammation and subsequent 
fibrosis and, regardless of the etiology, a cytokine-rich environment caused by 
inflammation and infection is closely associated with hepatic fibrosis. HSC is 
considered the most important effecter cell associated with fibrogenesis in hepatic 
parenchyma including the interface between portal tracts and periportal hepatocytes, 
and the fibrous enlargement of portal tracts and fibrous extension from portal areas are 
closely associated with activated HSCs and their transformed version, myofibroblasts. 
Within portal tracts, in contrast, fibroblasts and fibrocytes are also important to the 
histogenesis of portal fibrosis. Several cytokines such as PDGF-B, CTGF, TGF-β, 
endothelin-1, and MCP-1, are reported as fibrogenetic factors in liver.5 These cytokines 
could chemoattract HSCs or directly activate the production of collagen in 
myofibroblasts.  
We have previously reported that human BECs possess receptors for 
inflammatory cytokines (IL-1β, IL-6, IFN-γ, and TNF-α) and an innate immune system 
consisting of TLRs.6, 8, 9 Therefore, in this study, we examined whether BECs contribute 
to hepatic fibrosis using cultured human BECs. Consequently, although mRNAs of all 
fibrogenic cytokines were detected in BECs, only the expression of MCP-1 was 
upregulated, by two proinflammatory cytokines (by IL-1β and to a lesser degree by 
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TNF-α) and all TLR ligands in an NF-κB-dependent manner. Because human BECs 
produced IL-1β when stimulated with TLR ligands,15 the biliary innate immune 
response is suggested to be a critical trigger of MCP-1 production. 
Bile ductules and their proliferation occur nonspecifically in various 
hepatobiliary diseases. In normal livers, a few bile ductules are recognizable in the 
portal tract, while in various hepatobiliary diseases, these ductular structures are often 
increased in number, to be termed “ductular proliferation” or “proliferating bile 
ductules”. Because ductular proliferation was found accompanying interface hepatitis 
and periductal fibrosis in chronic liver diseases, these biliary elements are thought to 
take part in disease progression. However, the exact association between ductular 
proliferation and hepatic fibrogenesis is still unknown. Immunohistochemistry revealed 
that MCP-1 was expressed in bile ductules in areas of interface hepatitis, whereas 
normal livers lacked these findings. The ductular reaction predominantly corresponded 
to interface hepatitis in various chronic hepatobiliary diseases and these areas were rich 
in several cytokines caused by immune-mediated (necro)inflammatory reactions against 
virus-infected hepatocytes and bile-derived PAMPs. Therefore, these 
microenvironments are suitable for the production of MCP-1 in proliferating bile 
ductules at the interface.  
In damaged liver, HSCs are activated, proliferate, and migrate into the injured 
area in response to the chemoattractive effects of chemokines. MCP-1 is a chemokine 
attracting monocyte/macrophages and plays a role in persistent inflammation in chronic 
liver diseases. Marra et al.,3 reported that MCP-1 attracts HSCs, particularly activated 
HSCs, to the liver. Innate immunity is known to promote liver fibrosis and, as its 
mechanism, HSCs are reported to produce MCP-1 via TLR9 signaling.16 In this study, 
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immunohistochemistry using liver sections from patients with CVH and PBC revealed 
that αSMA-positive activated HSCs (myofibroblasts) were scattered and accumulated 
around MCP-1-expressing bile ductules in areas showing interface hepatitis. This 
finding suggests that MCP-1 derived from BECs plays a role in the chemoattraction of 
HSCs.  
A recent report demonstrated that hepatocytes are also a source of MCP-1 and 
that hepatocyte-derived MCP-1 induced by a hydrophobic bile acid, taurocholate, 
chemoattracts HSCs and is associated with the liver fibrosis under cholestatic conditions 
in cases of pediatric cholestatic liver disease such as biliary atresia. Our 
immunohistochemical study also confirmed the expression of MCP-1 in periportal 
hepatocytes, but, in the early stage of CVH and PBC, the MCP-1 derived from bile 
ductules is speculated to the major effecter, compared with that from hepatocytes, based 
on the intensity of MCP-1 immunostaining. We also examined the effect of bile acids 
on the production of MCP-1 in cultured BECs. No any bile acids affected the MCP-1 
expression in BECs, suggesting that cholestasis could not directly induce the production 
of MCP-1 in BECs, differing from hepatocytes. 
Portal fibroblasts located in portal tracts are fibrogenic cells distinct from HSCs 
and may be important mediators of biliary fibrosis and cirrhosis. Recently, Kruglov et 
al,17 reported that portal fibroblasts express functional receptors for MCP-1 that are 
distinct from CCR2 and that the secretion of MCP-1 by BECs induces myofibroblastic 
transdifferentiation of portal fibroblasts. In fact, the expression of MCP-1 was found in 
some interlobular bile ducts as well as bile ductules within portal tracts in CVH and 
PBC (data not shown). This finding suggests that MCP-1-dervied from BECs of these 
interlobular bile ducts is associated with the migration and activation of portal 
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fibroblasts. However, we speculate that the fibrogenesis associated with portal 
fibroblasts is mainly associated with the histogenesis of portal sclerosis and expansive 
fibrous enlargement of portal tracts, not the fibrous extension accompanying interface 
hepatitis from portal tracts. The close correlation between MCP-1-positive bile ductules 
and αSMA-positive activated HSCs in the interface area shown in this study supports 
our contention. Moreover, we examined CHF as a control diseased liver in this study. 
CHF is different from cirrhosis in which no abnormal biliary channels are seen. In 
portal tracts of CHF, irregular and newly proliferating bile ducts and ductules rather 
than congenitally abnormal ductal plates, and cholestasis in these bile ductules are 
found. But, in parenchyma, the features of chronic cholestasis and interface changes are 
not prominent. Our previous study reported that the fibrogenesis of CHF is associated 
with intraportal heparan sulfate proteoglycan and CTGF, but not periportal HSCs.14 It is 
true that although proliferating bile ductules were scattered within portal tracts, MCP-1 
expression in bile ductules and αSMA-positive HSCs were not found in CHF, 
suggesting that the MCP-1-mediated migration of HSCs limited in proliferating bile 
ductules accompanying interface hepatitis of chronic inflammatory hepatobiliary 
diseases, but not associated with the fibrogenesis in sole cholestatic liver diseases 
lacking interface changes such as CHF. 
Because the receptor of MCP-1, CCR2, is not expressed in human HSCs, HSC 
migration by MCP-1 occurs independent of CCR2 via an unknown receptor for MCP-1, 
instead of by CCR2.3 In fact, double immunohistochemistry in this study revealed that 
the expression of CCR2 is found not in αSMA-positive HSCs, but in CD68-positive 
Kupffer cells, suggesting that MCP-1-dervied from BECs could chemoattract Kupffer 
cells. As mentioned, portal fibroblasts within portal tracts also lack CCR2, but could be 
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attracted by MCP-1 derived from BECs in a CCR2-independent manner.17 In contrast, 
Seki et al.,18 reported that both Kupffer cells and HSCs express CCR2 in mice, but that 
these differences might be explained by differences between humans and mice. 
Various types of inflammation including infection-triggered inflammation are 
causative factors to induce hepatic fibrosis in chronic liver diseases. Particularly, HSCs 
are critical for hepatic fibrogenesis and MCP-1 is an important cytokine associated with 
HSC migration in fibrogenic areas. Therefore, the identification of MCP-1-producing 
cells and the clarification of the mechanism of MCP-1 production are mandatory to help 
regulate hepatic fibrosis and treat liver fibrosis. This study revealed that BECs are a 
source of MCP-1 in some hepatobiliary diseases and the production of MCP-1 is 
induced by inflammatory cytokines and biliary innate immune responses. Proliferating 
bile ductules are thought to be part of a non-specific reaction in various hepatobiliary 
diseases, but this study suggests that they are closely associated with the progression of 
periportal fibrosis via MCP-1 derived from biliary innate immunity. Because MCP-1 is 
thought to be a key mediator of hepatic fibrosis, it is a potential therapeutic target in 
inflammatory hepatobiliary diseases with hepatic fibrosis. 
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Take home messages 
- Biliary epithelial cells express several fibrogenic cytokines (MCP-1, PDGF-B, CTGF, 
TGF-β1, and endothelin-1), but only MCP-1 expression is upregulated by biliary innate 
immune reaction and proinflammatory cytokines (IL-1β and TNF-α).  
- Proliferating bile ductules in interface areas expressed MCP-1 in diseased livers 
accompanying αSMA-positive activated HSCs.  
- MCP-1 derived from biliary epithelial cells plays an important role in the recruitment of 
hepatic stellate cells (HSCs) to interface areas and the activation of HSCs resulting in the 
progression of periportal fibrosis. 
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Table 1    Primers used for RT-PCR and quantitative PCR 
 
--------------------------------------------------------------------------------------------------------- 
 Transcript                Primers                         Product size (bp) 
--------------------------------------------------------------------------------------------------------- 
MCP-1     Forward 5’- CTGAATTTTGTTTGTTGATGTGAAA -3’ 128 
Reverse 5’- GCAATTTCCCCAAGTCTCTG-3’   
PDGF-B  Forward 5’- GAGGACCTCTCAGCATAGCC -3’   135 
Reverse 5’- GGGGTTTTCTCCAGTCTGTG -3’ 
CTGF   Forward 5’- GCAGGCTAGAGAAGCAGAGC-3’   153 
Reverse 5’- ATGTCTTCATGCTGGTGCAG -3’ 
TGF-β1  Forward 5’- CAGAAATACAGCAACAATTCCTGG-3’ 186 
Reverse 5’- TTGCAGTGTGTTATCCCTGCTGTC-3’ 
endothelin-1  Forward 5’- CCATGAGAAACAGCGTCAAA -3’  213 
Reverse 5’- AGTCAGGAACCAGCAGAGGA-3’ 
GAPDH  Forward 5’- GCACCGTCAAGGCTGAGAAC-3’   142 
Reverse 5’- ATGGTGGTGAAGACGCCAGT-3’ 
--------------------------------------------------------------------------------------------------------- 
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Table 2    Stimulants 
------------------------------------------------------------------------------------------- 
Stimulants                      Concentration       Supplier 
------------------------------------------------------------------------------------------- 
Cytokines     
IL-1β          1,000U/ml  PerpoTech 
IL-6          1,000U/ml  PerpoTech 
IFN-γ          1,000U/ml  PerpoTech 
TNF-α          1,000U/ml  PerpoTech 
 
PAMPs 
LPS (TLR4 ligand)          1μg/ml        Invitrogen 
Pam3CSK4(TLR1/2 ligand)        100ng/ml  Invitrogen 
poly(I:C) (TLR3 ligand)    25μg/ml  Invitrogen 
 
Bile acid 
taurochenodeoxycholic acid (TCDC)  200μM  Calbiochem 
taurocholic acid (TC)     200μM  Calbiochem 
taurodeoxycholic acid (TDC)       200μM  Calbiochem 
tauroursodeoxycholic acid (TUDC)   200μM  Calbiochem 
--------------------------------------------------------------------------------------------- 
PerpoTech PeproTech, London, UK.  Invitrogen, San Diego, CA, USA. 
Calbiochem, Darmstadt, Germany. 
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Fig.1  Detection of fibrogenic cytokines in cultured human BECs. The two human 
biliary epithelial cell lines (BEC1 and BEC2) express all mRNAs of fibrogenic 
cytokines (MCP-1, PDGF-B, CTGF, TGF-β1, and endothelin-1) and the internal 
control (GAPDH) under basal conditions. Each PCR product showed the 
predicted size as a single band. Negative controls (NC) were obtained by 
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Fig.2  Quantitative PCR analysis for mRNA of fibrogenic cytokines (MCP-1, PDGF-B, 
CTGF, TGF-β1, and endothelin-1). MCP-1 expression alone was upregulated by 
stimulation with TLR ligands (LPS, Pam3CSK4, and poly(I:C)) and cytokines 
(IL-1β and TNF-α). No bile acids (TCDC, TC, TDC, or TUDC) significantly 
upregulated MCP-1 mRNA expression. Other fibrogenic cytokines were not 
affected by any stimulants. Lower figure denotes that Pam3CSK4-induced 
upregulation of MCP-1 mRNA expression was inhibited by pretreatment with an 









Fig.3  Measurement of MCP-1 protein by ELISA. After stimulation with LPS, 
Pam3CSK4 (Pam3), poly(I:C), and IL-1β for 24 hours, the concentration of 
MCP-1 protein in cultured supernatants of human biliary epithelial cells was 








Fig.4  Immunohistochemistry for MCP-1 (A, C, and E) and αSMA (B, D, and F). A 
and B; HCV-related chronic viral hepatitis. Proliferating bile ductules at the 
interface of periportal areas express MCP-1(A, arrows) and αSMA-positive cells 
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showing hepatic stellate cell (HSC) morphology are found in the same area (B, 
arrows). In contrast, αSMA-positive HSCs are not found in periportal 
parenchyma lacking bile ductules (asterisks). C and D; primary biliary cirrhosis. 
MCP-1-positive proliferating bile ductules and αSMA-positive cells are 
intermingled (arrows). E and F; congenital hepatic fibrosis. No biliary bile ducts 
or ductules express MCP-1 and no αSMA-positive HSCs are found in periportal 
areas (asterisks). The expression of αSMA is limited in portal tracts (lower 
right).  




Fig.5 Double immunohistochemistry using CVH livers. A, B, C are MCP-1 receptor 
(CCR2, green), αSMA (red), and merged image, respectively, and double 
positive cells indicating CCR2-positive hepatic stellate cells (yellow) are not 
found. D, E, and F are CCR2 (green), CD68 (red), and merged image, 
respectively, and double positive cells indicating CCR2-positive Kupffer cells 
(yellow) are scattered (arrows). 
